World's Best Scientists 2026 revealed!
Kazuhiko Nakagawa

Kazuhiko Nakagawa

Award Badge
Medicine
Japan
2023

D-Index & Metrics

Medicine

D-Index
116
Citations
71814
World Ranking
4275
National Ranking
88

Kazuhiko Nakagawa publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kazuhiko Nakagawa sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,221 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kazuhiko Nakagawa D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kazuhiko Nakagawa sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 116 D-Index — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Japan Leader Award

Overview

Kazuhiko Nakagawa is affiliated with Kindai University in Japan and has an extensive research portfolio primarily in the field of Medicine. Their work spans several subfields including Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery, and Molecular Biology.

Their research focuses on major topics within oncology and respiratory medicine, such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Gastric Cancer Management and Outcomes

Kazuhiko Nakagawa has coauthored papers frequently with the following researchers:

  • Nobuyuki Yamamoto (110 joint publications)
  • Hidetoshi Hayashi (84 joint publications)
  • Kazuto Nishio (55 joint publications)
  • Kazuko Sakai (41 joint publications)
  • Yasutaka Chiba (40 joint publications)

The scientist has contributed numerous articles to the following publication venues:

  • Annals of Oncology (37 publications)
  • Journal of Clinical Oncology (25 publications)
  • Journal of Thoracic Oncology (23 publications)
  • JTO Clinical and Research Reports (16 publications)
  • Lung Cancer (11 publications)

Among the noted recent papers authored are:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020, The Lancet Oncology)
  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer (2021, New England Journal of Medicine)
  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial (2022, The Lancet Oncology)
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer (2020, JAMA Oncology)
  • Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies (2020, International Journal of Cancer)

Kazuhiko Nakagawa also has contributions to academic literature through book publications, including a title on environmental ecology:

  • Ecología, medio ambiente y sustentabilidad (2023), published by Universidad Nacional Autónoma de México, Secretaría de Desarrollo Institucional eBooks

Best Publications

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

    Yi-Long Wu;Ying Cheng;Xiangdong Zhou;Ki Hyeong Lee

  • Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

    Koji Haratani;Hidetoshi Hayashi;Yasutaka Chiba;Keita Kudo

  • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

    Takashi Seto;Terufumi Kato;Makoto Nishio;Koichi Goto

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

    Toyoaki Hida;Hiroshi Nokihara;Masashi Kondo;Young Hak Kim

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

    Kimio Yonesaka;Kreshnik Zejnullahu;Isamu Okamoto;Taroh Satoh

  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

    Takashi Seto;Katsuyuki Kiura;Makoto Nishio;Kazuhiko Nakagawa

  • CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

    Noriyuki Masuda;Masahiro Fukuoka;Yoko Kusunoki;Kaoru Matsui

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

    Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  • Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Riichiroh Maruyama;Yutaka Nishiwaki;Tomohide Tamura;Nobuyuki Yamamoto

  • Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

    Shinzoh Kudoh;Koji Takeda;Kazuhiko Nakagawa;Minoru Takada

Frequent Co-Authors

Isamu Okamoto
Isamu Okamoto Kyushu University
Kazuto Nishio
Kazuto Nishio Kindai University
Masahiro Fukuoka
Masahiro Fukuoka Kindai University
Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)
Satoshi Morita
Satoshi Morita Kyoto University
Tetsuya Mitsudomi
Tetsuya Mitsudomi Kindai University
Tony Mok
Tony Mok Chinese University of Hong Kong
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a future in Medicine or related healthcare fields, online degrees offer flexible, diverse career options beyond traditional medical school routes. Healthcare administration is one popular path, with several accredited mha programs available online. These programs equip graduates for leadership roles in hospitals and healthcare organizations.

Nursing professionals also benefit from streamlined online education. For RNs looking to advance, there are rn to bsn without clinicals programs, making it easier to earn a BSN while balancing work and life commitments.

Those aiming for the highest levels of nursing practice can explore the fastest online dnp programs for rapid career advancement. If flexibility and manageable workloads are your priority, consider the easiest dnp programs.

These online degrees open doors to specialized roles in patient care, administration, and leadership, making them valuable alternatives and complements to studying Medicine in the USA.

Best Scientists Citing Kazuhiko Nakagawa

Trending Scientists

Recently Published Articles